Edgewise Therapeutics
Business Services · Colorado, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1715 38th St, Boulder, Colorado, 80301, ...Phone Number
(720) 262-7002Website
www.edgewisetx.comRevenue
$24.7 MillionStock Symbol
EWTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
3
2
1
About Edgewise Therapeutics
EDGEWISE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. EDGEWISE has combined its expertise in muscle biology and small molecule engineering to build a proprietary, muscle focused drug discovery platform. The platform utilizes custom-built systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company is based in Boulder, CO.Explore more
Edgewise Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Edgewise Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Edgewise Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Edgewise Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Edgewise Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Edgewise Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Edgewise Therapeutics is spiking on competitors!
Earning: See what the market has to say on Edgewise Therapeutics recently announced quarterly report
Edgewise Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Edgewise Therapeutics launches new products
Recommended Actions
Find VP level buyers at Edgewise Therapeutics
Find more new buyers
Compare Similar Companies to Edgewise Therapeutics
Compare insights from companies similar to Edgewise Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Edgewise Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Edgewise Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Edgewise Therapeutics.
Edgewise Therapeutics financials insights
Gather financial insights about Edgewise Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$15.5M
2019
Series B
$50M
2020
Series C
$95M
2021
Stock Offering
$202.4M
Edgewise Therapeutics Tech Stack
A closer look at the technologies used by Edgewise Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Earnings, Clinical Operations, Finance
Open Position
Open Position
Edgewise Therapeutics News & Media
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage...Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the...Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential...Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dyst
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Edgewise Therapeutics
Sign Up For FreeTo access detailed company insights
EDGEWISE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. EDGEWISE has combined its expertise in muscle biology and small molecule engineering to build a proprietary, muscle focused drug discovery platform. The platform... Read More
